ArticleJournal of experimental & clinical cancer research : CR2022

Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.

Capucine Baldini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.